1032754-93-0

GDC-0980 (RG7422)是一种有效的，I型PI3K抑制剂，作用于PI3Kα/β/δ/γ，IC50分别为5 nM/27 nM/7 nM/14 nM，也抑制mTOR，K_i为17 nM，高选择性作用于其他PIKK家族激酶。Phase 2。

GDC-0980 shows the potent and selective inhibitory activities against class I PI3K and mTOR kinase versus a large panel of kinases with K_i of 17 nM for mTOR and IC50 of 5 nM, 27 nM, 7 nM, and 14 nM for PI3Kα, β, δ, and γ, respectively. In vitro, GDC-0980 significantly inhibits cell proliferation in PC3 and MCF7 cells with IC50 of 307 nM and 255 nM, respectively. A recent study shows that GDC-0980 reduces cancer cell viability by inhibiting cell-cycle procession and inducing apoptosis with most potency in prostate (IC50 < 200 nM 50%), <500 nM 100%), breast (IC50 <200 nM 37%, <500 nM 78%) and NSCLC lines (IC50 <200 nM 29%, <500 nM 88%) and less potency in pancreatic (IC50 <200 nM 13%, <500 nM 67%) and melanoma cell lines (IC50 <200 nM 0%, <500 nM 33%).

In both PC-3 and MCF-7 neo/HER2 xenograft models, GDC-0980 at a dose of 1 mg/kg, exhibits significant antitumor activity by causing tumor growth delay. Furthermore, GDC-0980 results in tumor stasis or regressions at the maximum tolerated dose of 7.5 mg/kg. In mice, intravenous GDC-0980 administration at 1 mg/kg leads to low clearance (Cl_p: 9.2 mL/min/kg, V_ss: 1.7 L/kg). While, oral administration at 5 mg/kg in 80% PEG400 and at 50 mg/kg as a crystalline suspension in 0.5% methylcellulose/0.2% Tween-80 also results in favorable pharmacokinetic parameters.

GDC-0980 (RG7422) is a potent, selective, and orally available inhibitor of PI3Kα, β, δ, γ and mTOR.

Apitolisib (GDC-0980, RG7422, GNE 390)是一种有效的，I型PI3K抑制剂，作用于PI3Kα/β/δ/γ，无细胞试验中IC50分别为5 nM/27 nM/7 nM/14 nM，也是mTOR抑制剂，无细胞试验中Ki为17 nM，比作用于其他PIKK家族激酶选择性高。Apitolisib 在胰腺癌细胞中可同时激活自噬与凋亡。Phase 2。

Target	Value
p110α (Cell-free assay)	5 nM
p110δ (Cell-free assay)	7 nM
p110γ (Cell-free assay)	14 nM
mTOR (Cell-free assay)	17 nM(Ki app)
p110β (Cell-free assay)	27 nM

GDC-0980对I类PI3K和mTOR激酶比对其他大多数激酶表现出有效的选择性抑制作用，对mTOR的K _i 为17 nM，对PI3Kα，β，δ，和γ的IC50 分别为5 nM，27 nM，7 nM，和14 nM。在体外，GDC-0980显著抑制PC3和MCF7细胞的细胞增殖，IC50分别为307 nM和255 nM。一项最近的研究表明，GDC-0980通过抑制细胞周期进程，并诱导细胞凋亡降低癌细胞活性，在前列腺癌(IC50 < 200 nM 50%，<500 nM 100%)，乳腺癌(IC50 <200 nM 37%，<500 nM 78%) 和NSCLC(IC50 <200 nM 29%，<500 nM 88%)中具有最大效能，在胰腺癌(IC50 <200 nM 13%，<500 nM 67%) 和黑色素瘤细胞系(IC50 <200 nM 0%，<500 nM 33%)中效能较低。

在PC-3和MCF-7 neo/HER2异种移植模型中，GDC-0980在1 mg/kg剂量下，通过引起肿瘤生长延迟，表现出显著的抗肿瘤活性。此外，GDC-0980导致肿瘤郁积或退化，最大耐受剂量为7.5 mg/kg。在小鼠体内，1 mg/kg GDC-0980静脉内给药导致低清除率(Cl _p : 9.2 mL/min/kg，V _ss : 1.7 L/kg)。同时，以5 mg/kg的80% PEG400溶液，或50 mg/kg在0.5%甲基纤维素/0.2% Tween-80中以晶体悬浮液口服给药，具有良好的药代动力学参数。